Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20921432 | 0.82 | PIK3CD (0.42) | PDK1KDM1ADRD1GLRA1CNR2 | |
| SCHEMBL17828068 | 0.82 | PIK3CD (0.42) | PDK1KDM1ADRD1GLRA1CNR2 | |
| SCHEMBL18556758 | 0.82 | PIK3CD (0.42) | PDK1KDM1ADRD1GLRA1CNR2 | |
| SCHEMBL932483 | 0.79 | PDK1 (0.40) | PDK1KDM1ADRD1GLRA1CNR2 | |
| SCHEMBL9801239 | 0.79 | PDK1 (0.43) | PDK1KDM1ADRD1GLRA1 | |
| SCHEMBL24737031 | 0.78 | DRD4 (0.36) | PDK1 | |
| SCHEMBL16445720 | 0.77 | ATM (0.46) | PDK1KDM1ADRD1GLRA1 | |
| SCHEMBL8227861 | 0.77 | PDK1 (0.38) | PDK1KDM1ADRD1GLRA1GRM2 | |
| SCHEMBL13415808 | 0.75 | — | — | |
| SCHEMBL9801457 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | PDK1 228/4885KDM1A 1630/4885DRD1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.